How do I tell if seizure medication side effects are too much?

Published by Unseen Progress, an independent publisher of caregiver research. Last reviewed 2026-05-10. Part of the epilepsy caregiver research overview.

Short answer. ASM side effects are "too much" when they meet either of two thresholds: (1) the impairment in daily functioning is comparable to or greater than the impairment the seizures themselves caused, or (2) the side-effect burden is producing secondary harms — academic decline, social withdrawal, depressed mood, refusal to take the medication — that compound across months. The literature consistently treats this as a legitimate clinical data point, not a soft preference, and recommends caregivers track side effects with the same structure as seizures (French et al., 2004; Wilner, 2008).

What the literature says about ASM side-effect prevalence

The AAN/AES treatment guidelines for new antiepileptic drugs (French et al., 2004) and the comparative tolerability data from large cohort studies converge on a few stable findings:

  • A meaningful share of patients experience cognitive, behavioural, or affective side effects at therapeutic doses — fatigue, slowed processing, irritability, mood lability, depression, attention problems, appetite changes.
  • The effect size varies substantially by drug. Topiramate and zonisamide are particularly associated with cognitive slowing; levetiracetam with irritability and mood changes; valproate with weight gain and tremor; phenobarbital and benzodiazepines with sedation. Lamotrigine is often (though not always) better tolerated cognitively.
  • Side effects often emerge during titration and partially resolve at steady state — the early weeks systematically over-state long-term burden. But they also can emerge or worsen with dose increases later in the trial.
  • Children and adolescents are particularly susceptible to behavioural side effects, and the ones the family sees may be invisible to the patient — the parent notices that homework now takes three hours; the child reports feeling fine.

These are not edge cases. They are part of the expected profile of effective ASMs, and the clinical decision is rarely "any side effect = wrong drug" but rather "is the trade-off acceptable for this patient at this dose?"

The trade-off frame the research treats as legitimate

A child who was having two seizures a month and is now having none but is also failing a grade, withdrawing from friends, or visibly miserable has not necessarily improved. The literature on epilepsy outcomes — particularly the long-term cohort work — emphasises that seizure control is a means, not an end. The end is functional life. A regimen that controls seizures while destroying school performance, social participation, or mental health is not a successful regimen.

Caregivers often feel they cannot raise side effects without seeming to undervalue seizure control. The research is explicit that this framing is wrong: tolerability is one of the four criteria for an adequate trial in the ILAE consensus (Kwan et al., 2010), and a drug that is intolerable has not been adequately tried — it has been intolerable. Reporting intolerability is part of clinical decision-making, not a complaint about clinical decision-making.

What "too much" looks like when measured

The structured way the literature recommends operationalising side effects is with daily ratings on the 2–4 dimensions most relevant to the patient. For most paediatric patients, these are:

  • Alertness and processing speed — rated 1–5, ideally with a daily anchor (e.g. how long homework took, how the morning routine went)
  • Mood and irritability — rated 1–5, with notes on specific events
  • Schoolwork or work performance — concrete markers (grades, missed assignments, supervisor feedback) rather than impression
  • Appetite, weight, sleep, and any drug-specific physical effects — tremor, hair changes, rash, gastrointestinal symptoms

The data this produces makes the neurology conversation specific. Instead of "he seems off," the conversation becomes "frequency is down 70% from baseline, but alertness is down two points and his English grade has dropped from B to D." That is a clinical data point a neurologist can act on. Most will adjust dose, switch drugs, or accept the trade-off based on family priorities — but they need the data to make that call.

What the literature flags as warning thresholds

Across the clinical guidance, certain side effects warrant prompt contact with the prescribing neurologist regardless of seizure benefit:

  • Suicidal ideation or new-onset depression. ASMs as a class carry a small but real elevated risk of suicidal ideation (FDA class warning, 2008). Any new ideation in a patient on ASMs is a clinical emergency.
  • Rash, especially with lamotrigine. Stevens-Johnson syndrome and toxic epidermal necrolysis are rare but life-threatening and almost always emerge in the first 8 weeks. Any new rash on lamotrigine warrants stopping the drug pending evaluation.
  • Mood or behaviour change severe enough to disrupt school, family, or self-care. Particularly common with levetiracetam; usually resolves on switching.
  • Persistent sedation that does not resolve over 4–6 weeks. Either the dose is too high, or the drug is wrong for the patient.
  • Memory or processing changes that affect learning or work. Particularly common with topiramate and zonisamide; the family is often the first to notice.
  • Significant weight change in either direction. Valproate and pregabalin trend toward gain; topiramate and zonisamide toward loss; both can affect long-term health independent of seizure control.

Distinguishing these from tolerable side effects is the clinical conversation. The point is not to abandon a drug at the first sign of any effect — most settle — but to treat persistent, functionally limiting effects as data the regimen needs to respond to.

The "is it the drug or is it epilepsy?" problem

Children and adults with epilepsy have higher baseline rates of attention, mood, and learning difficulties than the general population, independent of medication. When a child on a new ASM is struggling at school, the question of whether the struggle predates the drug, was caused by it, or reflects the underlying neurology is genuinely hard. The research-backed approach is to establish a pre-medication baseline on the same dimensions before starting the drug, so that subsequent changes have something to compare against. This is rarely possible at diagnosis (when starting medication is urgent), but it is possible before any subsequent dose change or switch.

Where a baseline is unavailable, the literature suggests using the temporal pattern: side effects tied to dose changes or new drug starts are usually drug-related; ones that pre-existed the change are usually not.

What the research suggests doing

1. Pick two to four side-effect dimensions relevant to this patient (alertness, mood, school, appetite are common starting points) and rate each daily on a 1–5 anchored scale. 2. Distinguish initiation/titration effects (often resolve in 4–6 weeks) from steady-state effects (do not resolve and represent the long-term burden). 3. Bring the side-effect data to every neurology appointment with the same structure as the seizure data. Lead with the comparison: "frequency change = X, alertness change = Y, mood change = Z." 4. Treat any new suicidal ideation, rash on lamotrigine, or severe behavioural change as a same-day call to the prescriber — not a wait-for-the-next-appointment item. 5. If side effects are persistent and functionally limiting at maximum tolerated dose, raise the trade-off explicitly. The ILAE definition of an adequate trial includes tolerability; an intolerable drug is not a failed drug, it is an untried one, and switching is appropriate.

Related questions

References

  • French, J. A., Kanner, A. M., Bautista, J., et al. (2004). Efficacy and tolerability of the new antiepileptic drugs: AAN/AES treatment guidelines. Neurology, 62(8), 1252–1260.
  • Kwan, P., Arzimanoglou, A., Berg, A. T., et al. (2010). Definition of drug resistant epilepsy: ILAE consensus. Epilepsia, 51(6), 1069–1077.
  • Wilner, A. N. (2008). Epilepsy in Clinical Practice: A Case Study Approach. Demos Medical.
  • U.S. Food and Drug Administration (2008). Suicidality and antiepileptic drugs — class labelling change for ASMs.

---

Unseen Progress publishes long-form caregiver research and builds research-backed daily trackers for the families covered. See the full epilepsy caregiver research overview for the complete framework.